文献速递小儿耳鼻咽喉头颈外科

实体器官移植后儿童扁桃体切除术结局:15年单中心经验

Tonsillectomy Outcomes in Children After Solid-Organ Transplantation: A 15-Year Single-Center Experience.
PubMed 文献 · Otolaryngol Head Neck Surg · 2023-01-19

该回顾性队列研究纳入2006至2021年接受扁桃体切除术/腺样体扁桃体切除术的110例肾、心或肝移植儿童,移植后淋巴增殖性疾病(PTLD)发生率为47.3%,其中25%无扁桃体肥大;移植年龄、移植器官、移植至手术间隔、免疫抑制药物、扁桃体大小或不对称在PTLD与良性肥大患者间无差异,术后并发症相似。

要点

  • 儿童实体器官移植后因任何指征行扁桃体切除术,PTLD发生率为47.3%。
  • 术前症状体征与PTLD组织病理诊断无关联。
  • 按移植器官和免疫抑制药物分层未发现PTLD及术后并发症差异。

核心结论

  • 儿童实体器官移植后因任何指征行扁桃体切除术,PTLD发生率为47.3%。
  • 术前症状体征与PTLD组织病理诊断无关联。
  • 按移植器官和免疫抑制药物分层未发现PTLD及术后并发症差异。

研究设计与样本

  • 回顾性队列研究,纳入2006至2021年在三级儿童医院有肾、心或肝移植史并接受扁桃体切除术/腺样体扁桃体切除术的儿童。
  • 共110例符合纳入标准,其中心脏移植46例、肾脏移植41例、肝脏移植19例、肝-肾联合移植4例。
  • 移植时平均年龄4.2岁,移植至扁桃体切除术/腺样体扁桃体切除术的平均时间间隔28.8个月。

主要发现

  • 52例(47.3%)诊断为移植后淋巴增殖性疾病(PTLD),其中25%无扁桃体肥大。
  • PTLD患者与良性扁桃体/腺样体肥大患者在移植年龄、移植器官、移植至手术时间间隔、免疫抑制药物、扁桃体大小或扁桃体不对称方面无差异。
  • 两组扁桃体切除术后并发症相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Solid-organ transplantation (SOT) has become the standard of care for children with terminal organ failure. Long-term immunosuppression has improved survival substantially but is associated with secondary malignancies and impaired wound healing. Our goal was to review the incidence, outcomes, complications, and rate of posttransplant lymphoproliferative disorder on pathologic examination following tonsillectomy/adenotonsillectomy (T/AT) in children after SOT. STUDY DESIGN: A retrospective cohort study. SETTING: Tertiary care children's hospital. METHODS: Data were extracted from charts of children with a history of kidney, heart, or liver transplantation, who underwent T/AT between 2006 and 2021. RESULTS: A total of 110 patients met the inclusion criteria, including 46 hearts, 41 kidneys, 19 livers, and 4 liver-and-kidney transplants. The mean age at transplantation was 4.2 years, and the mean transplantation-to-T/AT time interval was 28.8 months. The posttransplant lymphoproliferative disorder was diagnosed in 52 (47.3%) patients, and 25% of these had no tonsillar hypertrophy. There was no difference in age at transplantation, organ received, transplantation-to-T/AT time interval, immunosuppressive medications, tonsil size, or tonsillar asymmetry between patients diagnosed with the posttransplant lymphoproliferative disorder and patients with benign tonsillar/adenotonsillar hypertrophy. Posttonsillectomy complications were similar between the groups. CONCLUSION: The incidence of posttransplant lymphoproliferative disorder undergoing tonsillectomy for any indication was 47.3%. There was no association between preoperative signs and symptoms and the histopathological diagnosis of posttransplant lymphoproliferative disorder. Stratification by organ received and immunosuppressive medications did not identify differences among the groups relative to the incidence of posttransplant lymphoproliferative disorder and other postoperative complications.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Hazkani I, Hajnas N, Victor M, et al. Tonsillectomy Outcomes in Children After Solid-Organ Transplantation: A 15-Year Single-Center Experience. Otolaryngol Head Neck Surg. 2023. PMID: 36939520. doi:10.1002/ohn.193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。